Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, February 18, 2015
GlobeNewswire - Thu Feb 12, 1:49PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
IHUB Most Posted And Most Read Stocks Do Not Perform Well
Anthony Cataldo - at Seeking Alpha - Wed Feb 11, 8:43AM CST
PPHM: 1.28 (+0.03)
Zogenix Approval Sheds Light On Path For Elite Pharmaceuticals
Matt's Stocks - Seeking Alpha - Fri Feb 06, 7:00AM CST
The recent approval of a reformulated version of Zohydro has shed some light on the path that Elite Pharmaceuticals ( OTCQB:ELTP ) may be taking to garner approval. Elite Pharma noted to investors in November that some additional but small...
ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23)
Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market
Matt's Stocks - Seeking Alpha - Thu Jan 29, 7:06AM CST
The past year for Elite Pharmaceuticals ( OTCQB:ELTP ) has been quite remarkable. While the stock price has taken investors on a bit of a roller coaster ride, the company's business trajectory has been exceptional. In the past year, we have seen...
EGLT: 10.60 (+0.58), ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), ACUR: 0.55 (+0.01)
Elite Pharmaceuticals Announces First Shipment of Generic Isradipine Capsules
GlobeNewswire - Thu Jan 15, 9:46AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
Elite Pharmaceuticals receives second abuse deterrent drug formulation patent in Canada
M2 - Wed Dec 17, 8:09AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) announced on Tuesday that it has received the second Canadian Patent, Number 2,541,371, entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" to expand the scope and reach of its patent estate internationally.
Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
GlobeNewswire - Tue Dec 16, 7:38AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
GlobeNewswire - Wed Dec 03, 8:56AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 19, 4:49PM CST
Elite Pharmaceuticals achieves 8% increase in revenues for Q2 fiscal 2015
M2 - Wed Nov 19, 6:15AM CST
Specialist pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) disclosed on Tuesday that its consolidated revenues was USD1.3m for the second quarter of fiscal year 2015 ended 30 September 2014.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
GlobeNewswire - Tue Nov 18, 5:24PM CST
Revenues increase by 8%
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, November 19, 2014
GlobeNewswire - Thu Nov 13, 4:02PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
Elite Pharmaceuticals Announces New Management Appointments
GlobeNewswire - Fri Oct 24, 6:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
GlobeNewswire - Tue Sep 09, 6:04AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
Elite Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
GlobeNewswire - Wed Sep 03, 12:47PM CDT
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) a specialty pharmaceutical company developing a pipeline of pharmacological abuse deterrent opioids with niche generic products, today announced that Nasrat Hakim, Elite's President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 16 Annual Healthcare Conference on Tuesday, September 9, 2014 at 2:55 PM Eastern Time. The conference is being held at The New York Palace Hotel in New York City.
OTC Daily Trading News: Evoq Properties, Inc. MedBox, Inc. LabStyle Innovations Corp, MyEcheck, Inc. Elite Pharmaceuticals, Inc.
PR Newswire Europe - Tue Aug 19, 10:11AM CDT
LONDON, August 19, 2014 /PRNewswire/ --
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015
GlobeNewswire - Thu Aug 14, 3:14PM CDT
Revenues Increase by 61%, Product Development on Schedule
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on August 18, 2014
GlobeNewswire - Wed Aug 13, 6:09AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
Elite Pharmaceuticals reports launch of pivotal bioequivalence study of ELI-201 in healthy volunteers to address issues in prescription drug abuse
M2 - Wed Jul 16, 9:08AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) disclosed on Tuesday the dosing of the first volunteer in a pivotal bioequivalence study of ELI-201 utilising its proprietary pharmacological abuse deterrent technology.